High Flow Nasal Oxygen Versus VNI in Acute Hypercapnic Cardiogenic Pulmonary Edema (OPTICAP)
High Flow Nasal Oxygen Versus VNI for Emergency Department Treatment of Acute Hypercapnic Cardiogenic Pulmonary Edema With Respiratory Failure: a Multicenter Randomized Non Inferiority Trial
Sponsor: Fisher and Paykel Healthcare
This NA trial investigates Acute Cardiogenic Pulmonary Edema and Hypercapnic Respiratory Failure and is currently ongoing. Fisher and Paykel Healthcare leads this study, which shows 7 recorded versions since 2016 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status NA
-
Jul 2020 — Jan 2021 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jul 2018 — Jul 2020 [monthly]
Recruiting NA
▶ Show 2 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Recruiting NA
-
Jan 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Oct 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fisher and Paykel Healthcare
- University Hospital, Montpellier
For direct contact, visit the study record on ClinicalTrials.gov .